223 related articles for article (PubMed ID: 17149719)
1. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.
Michaeli S; Oz G; Sorce DJ; Garwood M; Ugurbil K; Majestic S; Tuite P
Mov Disord; 2007 Feb; 22(3):334-40. PubMed ID: 17149719
[TBL] [Abstract][Full Text] [Related]
2. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance relaxometry in Parkinson's disease.
Mondino F; Filippi P; Magliola U; Duca S
Neurol Sci; 2002 Sep; 23 Suppl 2():S87-8. PubMed ID: 12548357
[TBL] [Abstract][Full Text] [Related]
5. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
6. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
[TBL] [Abstract][Full Text] [Related]
7. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
8. Structural changes in the midbrain with aging and Parkinson's disease: an MRI study.
Sohmiya M; Tanaka M; Aihara Y; Okamoto K
Neurobiol Aging; 2004 Apr; 25(4):449-53. PubMed ID: 15013565
[TBL] [Abstract][Full Text] [Related]
9. Potential role of high-field MRI for studies in Parkinson's disease.
Schuff N
Mov Disord; 2009; 24 Suppl 2():S684-90. PubMed ID: 19877239
[TBL] [Abstract][Full Text] [Related]
10. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
[TBL] [Abstract][Full Text] [Related]
11. Quantitative estimation of regional brain iron with magnetic resonance imaging.
Martin WR
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S215-8. PubMed ID: 20082994
[TBL] [Abstract][Full Text] [Related]
12. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.
Cho ZH; Oh SH; Kim JM; Park SY; Kwon DH; Jeong HJ; Kim YB; Chi JG; Park CW; Huston J; Lee KH; Jeon BS
Mov Disord; 2011 Mar; 26(4):713-8. PubMed ID: 21506148
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI.
Wieler M; Gee M; Martin WR
Parkinsonism Relat Disord; 2015 Mar; 21(3):179-83. PubMed ID: 25534153
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging and spectroscopy in Parkinson's disease.
Martin WR
Adv Neurol; 2001; 86():197-203. PubMed ID: 11553978
[TBL] [Abstract][Full Text] [Related]
15. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
[TBL] [Abstract][Full Text] [Related]
16. Multispectral quantitative magnetic resonance imaging of brain iron stores: a theoretical perspective.
Jara H; Sakai O; Mankal P; Irving RP; Norbash AM
Top Magn Reson Imaging; 2006 Feb; 17(1):19-30. PubMed ID: 17179894
[TBL] [Abstract][Full Text] [Related]
17. T1rho and T2rho MRI in the evaluation of Parkinson's disease.
Nestrasil I; Michaeli S; Liimatainen T; Rydeen CE; Kotz CM; Nixon JP; Hanson T; Tuite PJ
J Neurol; 2010 Jun; 257(6):964-8. PubMed ID: 20058018
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Geng DY; Li YX; Zee CS
Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
[TBL] [Abstract][Full Text] [Related]
19. [Magnetic resonance imaging in Parkinson's disease--the evaluation of the width of pars compacta on T2 weighted image].
Moriwaka F; Tashiro K; Itoh K; Hamada T; Miyasaka K
Rinsho Shinkeigaku; 1992 Jan; 32(1):8-12. PubMed ID: 1628441
[TBL] [Abstract][Full Text] [Related]
20. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease.
Baudrexel S; Nürnberger L; Rüb U; Seifried C; Klein JC; Deller T; Steinmetz H; Deichmann R; Hilker R
Neuroimage; 2010 Jun; 51(2):512-20. PubMed ID: 20211271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
